CalciMedica sets mid-2027 targets for PH data and CM5480 IND, cash runs into H2 2027
Third quarter update details Phase 1b pulmonary hypertension trial plans, FDA alignment on a Phase 2b acute pancreatitis design, and $13.8 million in cash.
SEC filing